Designed around uninterrupted operation, automation, and sustainability, the site offers a blueprint for the next generation of commercial autologous manufacturing.
The collaboration will apply automated manufacturing and quality control technologies to support development of an investigational gene-edited therapy for Friedreich’s ataxia.
The completed program established manufacturing processes and analytical methods to support future GMP production of an investigational Huntington’s disease therapy.
